


Programs
Aiming to treat β-thalassemia and sickle cell disease with gene-edited hematopoietic stem cells




Press Releases
May 16, 2022
May 12, 2022
May 09, 2022
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results



Join Our Team
We're looking for energetic, collaborative and talented people who like challenges, want to make a difference and have a track record of delivering results. View open opportunities


You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.